Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes

We previously reported that dapagliflozin versus placebo as add‐on to saxagliptin plus metformin resulted in greater reductions in glycated haemoglobin (A1C), fasting plasma glucose (FPG) and body weight (BW) after 24 weeks of treatment in patients with type 2 diabetes (T2D). Here we report results...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2016-11, Vol.18 (11), p.1134-1137
Hauptverfasser:	Mathieu, C., Herrera Marmolejo, M., González González, J. G., Hansen, L., Chen, H., Johnsson, E., Garcia-Sanchez, R., Iqbal, N.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adamantane - administration & dosage Adamantane - adverse effects Adamantane - analogs & derivatives Adult Benzhydryl Compounds - administration & dosage Benzhydryl Compounds - adverse effects Blood Glucose - drug effects Blood Glucose - metabolism Body Weight - drug effects dapagliflozin Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Dipeptides - administration & dosage Dipeptides - adverse effects Double-Blind Method DPP-4 inhibitor Drug Therapy, Combination Female Glucosides - administration & dosage Glucosides - adverse effects Glycated Hemoglobin A - drug effects Glycated Hemoglobin A - metabolism Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Male metformin Metformin - administration & dosage Metformin - adverse effects Middle Aged SGLT2 inhibitor Treatment Outcome type 2 diabetes Urinary Tract Infections - blood Urinary Tract Infections - chemically induced
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!